James Engelhart is CFO at Biohaven Pharmaceutical Holding Co Ltd. (BHVN). They have made 10 open-market trades across 1 company since 2017, most recently 2022-10-03.
CIK 0001704255
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $150K since 2017, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BHVN | 16,952 | $183K |
Shares reported on the most recent Form 4, priced at the 2022-01-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BHVN | SELL | 2021-12-10 | 2021-12-10 | $102.55 | $7.2M | +36.4% | +31.9% | +23.4% |
| BHVN | SELL | 2020-06-10 | 2020-06-12 | $66.09 | $9.7M | +7.9% | +7.2% | -5.2% |
| BHVN | BUY | 2019-06-27 | 2019-06-28 | $43.05 | $108K | -2.6% | +1.7% | -2.8% |
| BHVN | SELL | 2018-05-30 | 2018-05-30 | $35.00 | $175K | +3.2% | +12.9% | +8.1% |
| BHVN | SELL | 2018-05-07 | 2018-05-09 | $27.67 | $69K | +18.1% | +29.8% | +26.9% |
| BHVN | SELL · 10b5-1 | 2018-02-21 | 2018-02-23 | $29.60 | $16K | -9.3% | -31.2% | +3.6% |
| BHVN | SELL | 2018-01-22 | 2018-01-24 | $32.50 | $325K | +2.4% | +4.6% | -16.5% |
| BHVN | SELL | 2017-11-10 | 2017-11-14 | $26.28 | $235K | +5.9% | -10.5% | +24.7% |
| BHVN | SELL | 2017-11-09 | 2017-11-14 | $26.58 | $812K | +5.9% | -10.5% | +24.7% |
| BHVN | SELL | 2017-11-09 | 2017-11-14 | $26.70 | $577K | +5.9% | -10.5% | +24.7% |
| BHVN | BUY | 2017-05-09 | 2017-05-11 | $17.00 | $43K | +0.1% | -1.6% | +10.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.